Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops prescription medicines based on genetics and disease biology. Operating primarily in the United States, the company utilizes its proprietary gene knockout technology to identify potential drug targets and develop treatments for serious chronic conditions. Lexicon's pipeline spans multiple therapeutic areas, including cardiometabolism, neuropathic pain, and obesity. Key products and candidates include INPEFA (sotagliflozin) for heart failure, pilavapadin for diabetic peripheral neuropathic pain, and LX9851, an obesity treatment partnered with Novo Nordisk. The company's competitive position is anchored by its Genome5000 program, which has systematically evaluated thousands of genes to uncover novel biological pathways and therapeutic targets.
